Type I hereditary angio-oedema (HAE) is a rare autosomal dominant disorder characterized by recurrent bradykinin-mediated angio-oedema affecting the skin, respiratory system and gastrointestinal tract. Lanadelumab, a monoclonal antibody targeting plasma kallikrein to reduce bradykinin production, has shown efficacy in long-term prophylaxis (LTP) for patients aged 2 years and above, with a recommended dose of 300 mg biweekly. We present two cases of patients with type I HAE, poorly controlled with traditional LTP therapies, demonstrating complete response and extended attack-free intervals with lanadelumab, suggesting that administration intervals beyond 4 weeks may be feasible, improving patient quality of life and healthcare cost-effectiveness.
4 June 2025 in Clinical and Experimental Dermatology
This case report presents a healthy woman with ulcerative cribriform ulcers in the frontal area that were diagnosed as superficial granulomatous pyoderma. This disorder is an uncommon variant of pyoderma gangrenosum, which is more chronic and painless, with a particular lack of association with systemic illnesses. Exclusive facial involvement is exceedingly rare in this entity.